Search

Your search keyword '"Friedlander, Michael"' showing total 1,252 results

Search Constraints

Start Over You searched for: Author "Friedlander, Michael" Remove constraint Author: "Friedlander, Michael" Language english Remove constraint Language: english
1,252 results on '"Friedlander, Michael"'

Search Results

1. Cardinality-constrained structured data-fitting problems

7. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

8. Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry

10. Prognostic significance and accuracy of oncologists’ estimates of survival time in recurrent ovarian cancer

11. How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes

12. The Guide for the Perplexed, Part 3

16. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over

18. Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

22. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

24. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study

25. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

26. Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum

28. The impact of coding germline variants on contralateral breast cancer risk and survival

29. Profiling the immune landscape in mucinous ovarian carcinoma

30. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

31. Vaccine Effectiveness during Outbreak of COVID-19 Alpha (B.1.1.7) Variant in Men's Correctional Facility, United States

32. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

33. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

36. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

38. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.

39. Use of Dietary Supplements Before, During and After Treatment for Ovarian Cancer: Results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study.

40. Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival—A prospective cohort study in Australia.

41. Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas—a meta-analysis.

43. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer

44. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

46. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

48. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study

49. The Guide for the Perplexed, Part 2

Catalog

Books, media, physical & digital resources